The latest announcement is out from Elevation Oncology (ELEV).
Elevation Oncology will hold a conference call and webcast on August 6, 2024, to present preliminary results from their Phase 1 trial of EO-3021. Interested parties can find the presentation materials on the investor relations section of their website. The materials provided, however, are not considered part of this legal filing and will not be filed under the Exchange Act or integrated into other filings, except where explicitly referenced.
For detailed information about ELEV stock, go to TipRanks’ Stock Analysis page.
